5d 1m 3m 1y 5y 10y
Business Wire (Thu, 8:37AM)
Business Wire (Tue, 12:25PM)
Business Wire (Apr 8, 2014)
Business Wire (Mar 31, 2014)
Business Wire (Mar 20, 2014)
at CNBC.com (Mar 14, 2014)
at Fox Business (Mar 12, 2014)
at CNBC.com (Mar 12, 2014)
Business Wire (Mar 7, 2014)
Business Wire (Mar 4, 2014)
Business Wire (Mar 3, 2014)
Business Wire (Feb 28, 2014)
at CNBC.com (Feb 27, 2014)
Business Wire (Feb 24, 2014)
TEVA vs. ETF Alternatives
Monday, Mar 3111:05 AM
Monday, Mar 3111:05 AM| 1 Comment
- Shares of generic drug maker Momenta Pharmaceuticals (MNTA -11.4%) are down in early trading after the Supreme Court agrees to hear Teva's (TEVA +4.7%) appeal of a lower court's ruling invalidating its Copaxone patents.
- Without a reversal the product's exclusivity expires May 24.
Wednesday, Jan 294:57 AM
Wednesday, Jan 294:57 AM| Comment!
- Teva's (TEVA) shares are +2.7% in Tel Aviv after the FDA approved a 40 mg dose of the company's multiple sclerosis drug Copaxone that would be administered three times a week.
- Teva now plans to convert 57% of patients to the new regimen by the year-end from the daily dose of 20 mg.
- The longer-lasting regimen should help Teva cope with generic competition when Copaxone's patent protection expires in May. The higher-dosage version is protected until 2030. (PR)
Tuesday, Jan 143:37 PM
Tuesday, Jan 143:37 PM| 1 Comment
- Shares of Teva Pharmaceutical (TEVA +8.4%) are on their way to a solid session.
- The move higher is likely attributable to the reportedly upbeat tone struck at the JPMorgan Healthcare Conference, where the company presented today at 1:30 ET.
- According to chatter, the company says it is moving quickly with its new CEO.
- Also overheard during the presentation: The company is keeping the biosimilars business and remains interested in acquisitions.
- In other company news, TEVA says data published in the online scientific journal PLOS ONE suggests there are significant differences in biological and immunological effects between Copaxone and a purported generic." (PR)
Wednesday, Jan 812:46 PM
Wednesday, Jan 89:11 AM
Tuesday, Jan 79:58 AM
Tuesday, Jan 79:58 AM| 3 Comments
- BofA upgrades Perrigo (PRGO +1.2%) to Buy from Neutral. RBC starts the shares as a Top Pick, with a $187 price target.
- BofA upgrades Becton Dickinson (BDX +0.8%) to Neutral from Underperform.
- RBC upgrades Johnson & Johnson (JNJ +1.6%) to Outperform from Sector Perform. Price target is $104.
- Citi upgrades Varian Medical (VAR +1.6%) to Neutral from Sell.
- Roth starts ANI Pharma (ANIP +9.5%) at Buy. Price target is $27.
- RBC starts Teva (TEVA +0.1%) at Sector Perform. Price target is $39.
- RBC starts AcelRx (ACRX +2.5%) at Outperform. Price target is $15.
- RBC starts Mylan (MYL +2.3%) at Outperform. Price target is $50.
- RBC starts Allergan (AGN +1.3%) at Outperform. Price target is $131.
- RBC starts Impax Labs (IPXL +0.2%) at Sector Perform. Price target is $25.
Tuesday, Dec 172013, 12:17 PM
Tuesday, Dec 172013, 12:17 PM| 5 Comments
- Teva Pharmaceuticals (TEVA -0.1%) will be allowed to launch a generic version of Viagra on Dec. 11, 2017 (or earlier under certain circumstances) following a settlement of Pfizer's (PFE -0.1%) patent litigation case against the company. Teva will pay Pfizer a royalty for a license to produce the generic version. Other terms of the settlement are confidential.
- Press release
Monday, Dec 162013, 5:42 PM
Monday, Dec 162013, 12:46 PM|Monday, Dec 162013, 12:46 PM| Comment!
Monday, Dec 162013, 9:11 AM
Wednesday, Nov 202013, 3:15 PM
Wednesday, Nov 202013, 3:15 PM| 7 Comments
- Shares of Teva (TEVA +3.7%) are trading notably higher on the session.
- Helping the cause is Susquehanna, where analysts have upgraded the stock to Positive from Neutral.
- Price target is now $50 (from $43).
- Meanwhile, the rumor mill is alive with talk of a possible merger with either Mylan (MYL +0.8%) or Valeant (VRX +0.1%).
- "People are looking for the company to do something,” an S&P analyst quoted by Bloomberg says.
Friday, Nov 82013, 10:09 AM
Friday, Nov 82013, 10:09 AM| 2 Comments
- The risk-reward profile of Sanofi's (SNY -0.8%) MS treatment Lemtrada may not warrant approval, FDA staff says.
- Risks reportedly include "lifelong hypothyroidism, serious infusion reactions, melanoma and other malignancies, Graves’s ophthalmopathy and other autoimmune disorders, and prolonged increased susceptibility to infection." (full report)
- An Ad Com will take up the issue next Wednesday. The drug is approved in Europe.
- Down 70% on the news: CVRs ((GCVRZ)) on the drug.
- Competing relapsing MS treatments: Tecfidera and Tysabri (BIIB +1.1%) and Copaxone (TEVA +0.3%).
- For more, follow the discussion here on SA.
Thursday, Oct 312013, 8:52 AM
Thursday, Oct 312013, 8:52 AM| 2 Comments
- Teva Pharmaceutical (TEVA) manages to beat estimates for Q3 despite controversy over proposed job cuts and the CEO shakeup.
- Revenue for the period prints at $5.1B, up 2% Y/Y.
- Revenue growth by region: U.S., +4%; Europe, +4%; ROW, -8%.
- Global Copaxone sales rise 1% (flat ex-currency impact and -6% outside the U.S.).
- Revenue growth by product: Azilect, +21%; Nuvigil, -7%; Provigil, -58%; Treanda, +15%; ProAir, +3%; Qvar, +11%; Women's Health, +31%.
- Acting CEO Eyal Desheh says TEVA remains "committed to executing [the company's] strategy and diligently implementing changes [that] will ensure the growth of [the] business." (PR)
Wednesday, Oct 302013, 10:51 AM
Wednesday, Oct 302013, 10:51 AM| 2 Comments
- "We view this news as a significant setback ... as the company's recently implemented strategy to [get] back on a growth path, including recent accelerated cost reduction initiatives, could be called into question," Goldman's Jami Rubin says, regarding the resignation of Teva (TEVA -6.2%) chief Jeremy Levin.
- Rubin also says that "while investors have rewarded the heightened deal activity in the generic drug industry ... TEVA has not been moving quickly or aggressively enough to create shareholder value." This is reminiscent of Rubin's rationale for downgrading the shares back in July.
- Sell rating maintained.
- Price target is $40.
Wednesday, Oct 302013, 9:13 AM
Wednesday, Oct 302013, 6:54 AM
Wednesday, Oct 302013, 6:54 AM| 4 Comments
- Teva Pharmaceuticals's (TEVA) CEO Jeremy Levin has resigned just two days after the company denied a report that he was thinking of quitting due to a rift over strategy with Chairman Phillip Frost.
- Teva has appointed CFO Eyal Desheh as interim chief while it looks for a permanent successor to Levin.
- Teva's results are due out tomorrow.
- Shares are -4.4% premarket. (PR)
- View all 2 replies
Energysystems:: They requested that a generic not be allowed on the market til the SCOTUS decision; no word yet on whether that will happen.
Energysystems:: But I expected a bit of whipsaw action after that big run up of late. No real news, except the generic Lovaza being 1st to market.